Status:
ACTIVE_NOT_RECRUITING
Effectiveness and Tolerability of Eqwilate in Real-life Conditions
Lead Sponsor:
Octapharma
Conditions:
VWD - Von Willebrand's Disease
Eligibility:
All Genders
6+ years
Brief Summary
MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study
Eligibility Criteria
Inclusion
- The study will involve patients (≥ 6 years of age) from the participating centres treated with Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) during the time inclusion period will be opened. Patients will be of any VWD type, previously treated or untreated.
Exclusion
- N/A
Key Trial Info
Start Date :
November 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04106908
Start Date
November 27 2019
End Date
November 1 2026
Last Update
April 18 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Caen Study Site
Caen, France, 14033
2
Clamart Study Site
Clamart, France, 92141
3
Paris Study Site - Lariboisiere
Paris, France, 75010
4
Paris Study Site - Necker
Paris, France, 75015